OncoMatch/Clinical Trials/NCT07792980
AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients
Is NCT07792980 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for colon neoplasms.
The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3 supplementation before and after surgery can reduce postoperative infectious complications compared with placebo.Participants will take either MPRO3 or a placebo once daily for 13 weeks, from 1 week before surgery to 12 weeks after surgery. Researchers will compare the two groups to assess postoperative infectious complications, other clinical outcomes, and changes in the gut microbiome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Demographics
Prior therapy
Cannot have received: chemotherapy for colon cancer
A person who has received chemotherapy or radiotherapy for colon cancer before surgery
Cannot have received: radiotherapy for colon cancer
A person who has received chemotherapy or radiotherapy for colon cancer before surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07792980 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy for colon cancer, radiotherapy for colon cancer disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages